Similarly, the IMPOWER-010 trial showed a disease-free survival benefit with atezolizumab vs. placebo after adjuvant chemotherapy in patients with resected stage II–IIIA NSCLC, with more pronounced benefits in the subgroup whose tumors expressed PD-L1 on ≥1% of tumor cells [10], leading to the approval of atezolizumab in this setting by the U.S. Food and Drug Administration (FDA). The gene discussed is CD274; the disease is neoplasm.